Research Article
BibTex RIS Cite

Evaluation of side effects associated with global COVID-19 vaccines in Iraq

Year 2022, Volume: 26 Issue: 6, 1915 - 1922, 28.06.2025

Reyadh Al-rashıdı , Rusul A Alsaray Zeid Alsadoon Watheq N Alwan Wesam R Kadhum Ahmed Alaa Al-temimi

Abstract

Since the start of the pandemic of COVID-19, it was clear that vaccination was the best way to combat it. A few vaccines were produced and approved in the last year. Many questions about the vaccinations' efficacy and safety arose due to this unprecedented vaccine development effort. This study aimed to evaluate the short‐term side effects after receiving the available COVID-19 vaccines by the students of the Kut university college. This research was conducted as a cross-sectional, retrospective study using an online questionnaire distributed among COVID-19 vaccine recipients. The number of students who are enrolled in this study is 804, nearly (81%) of our study subjects were symptomatic after receiving the vaccination. Participants with a history of SARS‐CoV‐2 infection, comorbid diseases, females, non-smokers, and AstraZeneca vaccine receivers showed significantly (p<0.05) more severe side effects. In conclusion, the side effects described by our undergraduate students after receiving vaccinations from Pfizer BioNTech, Oxford AstraZeneca, and Sinopharm are similar to those reported in clinical trials, showing that these vaccines have safe profiles. More research is needed to assess the efficiency of current vaccinations in preventing SARS-CoV-2 reinfections.

Keywords

COVID-19 SARS-CoV-2 vaccine side effects

References

  • [1] Hatmal MM, Alshaer W, Al-Hatamleh MA, Hatmal M, Smadi O, Taha MO, Oweida AJ, Boer JC, Mohamud R, Plebanski M. Comprehensive structural and molecular comparison of spike proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and their interactions with ACE2. Cells. 2020; 9(12): 2638. [CrossRef]
  • [2] Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W. Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review. Clinical Medicine. 2021; 40:10, 11-13. [CrossRef]
  • [3] Graupensberger S, Abdallah DA, Lee CM. Social norms and vaccine uptake: College students’ COVID vaccination intentions, attitudes, and estimated peer norms and comparisons with influenza vaccine. Vaccine. 2021; 39(15): 2060-7. [CrossRef]
  • [4] Dal-Ré R, Caplan AL, Gluud C, Porcher R. Ethical and scientific considerations regarding the early approval and deployment of a COVID-19 vaccine. American College of Physicians; 2021. p. 258-60. [CrossRef]
  • [5] Ledford H, Cyranoski D, Van-Noorden R. The UK has approved a COVID vaccine-here's what scientists now want to know. Nature. 2020; 588(7837): 205-6. [CrossRef]
  • [6] Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020; 182(3): 713-21. e9. [CrossRef]
  • [7] Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, Maghfuri A, Algaissi A. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines. 2021; 9(6): 674. [CrossRef]
  • [8] Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID-19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021; 15(5): 102207. [CrossRef]
  • [9] Hatmal MM, Al-Hatamleh MA, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, Mohamud R. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomised, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines. 2021; 9(6): 556. [CrossRef]
  • [10] Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy. 2020; 5(1): 1-14. [CrossRef]
  • [11] Iftekhar EN, Priesemann V, Balling R, Bauer S, Beutels P, Valdez AC, Cuschieri S, Czypionka T, Dumpis U, Glaab E, Grill E, Hanson C, Hotulainen P, Klimek P, Kretzschmar M, Krüger T, Krutzinna J, Low N, Machado H, Martins C, McKee M, Mohr SB, Nassehi A, Perc M, Petelos E, Pickersgill M, Prainsack B, Rocklöv J, Schernhammer E, Staines A, Szczurek E, Tsiodras S, Gucht SV, Willeit P. A look into the future of the COVID-19 pandemic in Europe: an expert consultation. The Lancet Regional Health-Europe. 2021; 8: 100185. [CrossRef]
  • [12] Hernández AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Toxicology Reports. 2021; 8: 871-9. [CrossRef]
  • [13] Kelly BJ, Southwell BG, McCormack LA, Bann CM, MacDonald PDM, Frasier AM, Bevc CA, Brewer NT, Squiers LB. Predictors of willingness to get a COVID-19 vaccine in the US. BMC Infectious Diseases. 2021; 21(1): 1-7. [CrossRef]
  • [14] Hitti FL, Weissman D. Debunking mRNA vaccine misconceptions–an overview for medical professionals. The American Journal of Medicine. 2021. [CrossRef]
  • [15] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020. [CrossRef]
  • [16] Knoll MD, Wonodi C. Oxford–Astra Zeneca COVID-19 vaccine efficacy. The Lancet. 2021; 397(10269): 72-4. [CrossRef]
  • [17] Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomised, placebo-controlled, double-blind phase 1 study. Nature Medicine. 2021; 27(6): 1062-70. [CrossRef]
  • [18] Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. Morbidity and Mortality Weekly Report. 2021; 70(8): 283. [CrossRef]
  • [19] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021; 397(10269): 99-111. [CrossRef]
  • [20] Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases. 2021. [CrossRef]
  • [21] Chang W-H. A review of vaccine effects on women in light of the COVID-19 pandemic. Taiwanese Journal of Obstetrics and Gynecology. 2020; 59(6): 812-20. [CrossRef]
  • [22] Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 Vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020; 396(10267): 1979-93. [CrossRef]
  • [23] Kang YM, Lim J, Choe K-W, Lee K-D, Jo DH, Kim MJ, et al. Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study. Clinical and Experimental Vaccine Research. 2021; 10(3): 282. [CrossRef]
  • [24] Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccine. Diabetes/Metabolism Research and Reviews. 2021. [CrossRef]
  • [25] Ferrara P, Gianfredi V, Tomaselli V, Polosa R. The effect of smoking on humoral response to COVID-19 vaccines: a systematic review of epidemiological studies. Vaccines. 2022; 10(2): 303. [CrossRef]
  • [26] Nomura Y, Sawahata M, Nakamura Y, Kurihara M, Koike R, Katsube O, et al. Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine. Vaccines. 2021; 9(9): 1042. [CrossRef]
  • [27] Yamamoto S, Tanaka A, Ohmagari N, Yamaguchi K, Ishitsuka K, Morisaki N, et al. Use of heat-not-burn tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers. medRxiv. 2021. [CrossRef]
  • [28] Food, Administration D. Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment. US Food & Drug Administration; 2020.
There are 28 citations in total.

Details

Primary Language English
Subjects Pharmacology and Pharmaceutical Sciences (Other)
Journal Section Articles
Authors

Reyadh Al-rashıdı

Rusul A Alsaray

Zeid Alsadoon

Watheq N Alwan

Wesam R Kadhum

Ahmed Alaa Al-temimi

Publication Date June 28, 2025
Published in Issue Year 2022 Volume: 26 Issue: 6

Cite

APA Al-rashıdı, R., Alsaray, R. A., Alsadoon, Z., Alwan, W. N., et al. (2025). Evaluation of side effects associated with global COVID-19 vaccines in Iraq. Journal of Research in Pharmacy, 26(6), 1915-1922.
AMA Al-rashıdı R, Alsaray RA, Alsadoon Z, Alwan WN, Kadhum WR, Al-temimi AA. Evaluation of side effects associated with global COVID-19 vaccines in Iraq. J. Res. Pharm. June 2025;26(6):1915-1922.
Chicago Al-rashıdı, Reyadh, Rusul A Alsaray, Zeid Alsadoon, Watheq N Alwan, Wesam R Kadhum, and Ahmed Alaa Al-temimi. “Evaluation of Side Effects Associated With Global COVID-19 Vaccines in Iraq”. Journal of Research in Pharmacy 26, no. 6 (June 2025): 1915-22.
EndNote Al-rashıdı R, Alsaray RA, Alsadoon Z, Alwan WN, Kadhum WR, Al-temimi AA (June 1, 2025) Evaluation of side effects associated with global COVID-19 vaccines in Iraq. Journal of Research in Pharmacy 26 6 1915–1922.
IEEE R. Al-rashıdı, R. A. Alsaray, Z. Alsadoon, W. N. Alwan, W. R. Kadhum, and A. A. Al-temimi, “Evaluation of side effects associated with global COVID-19 vaccines in Iraq”, J. Res. Pharm., vol. 26, no. 6, pp. 1915–1922, 2025.
ISNAD Al-rashıdı, Reyadh et al. “Evaluation of Side Effects Associated With Global COVID-19 Vaccines in Iraq”. Journal of Research in Pharmacy 26/6 (June 2025), 1915-1922.
JAMA Al-rashıdı R, Alsaray RA, Alsadoon Z, Alwan WN, Kadhum WR, Al-temimi AA. Evaluation of side effects associated with global COVID-19 vaccines in Iraq. J. Res. Pharm. 2025;26:1915–1922.
MLA Al-rashıdı, Reyadh et al. “Evaluation of Side Effects Associated With Global COVID-19 Vaccines in Iraq”. Journal of Research in Pharmacy, vol. 26, no. 6, 2025, pp. 1915-22.
Vancouver Al-rashıdı R, Alsaray RA, Alsadoon Z, Alwan WN, Kadhum WR, Al-temimi AA. Evaluation of side effects associated with global COVID-19 vaccines in Iraq. J. Res. Pharm. 2025;26(6):1915-22.